Kornimate/medical-research-clean huggingface dataset:
comparison of de-epithelialized gingival graft with or without platelet rich fibrin in multiple gingival recessions

Conditions: Gingival Recession, Generalized

Summary: the aim of this study is to compare the clinical efficacy and patient reported outcome measures of de-epithelialized gingival graft (dgg) with or without platelet rich fibrin on treatment of multiple adjacent gingival recessions with coronally advanced flap (caf) technique.

fifteen patients with split-mouth multiple gingival recessions affecting at least 3 adjacent teeth will be treated with either dgg or dgg+prf. recession depth(rd) and width(rw), probing depth(pd), clinical attachment level(cal), keratinized tissue width (ktw), gingival thickness(gt), and percentage of root coverage (rc%) will be evaluated at 1, 3 and 6 months postoperatively. for patient reported outcome measurements, oral health impact factor-14 (ohip-14) scores, postoperative pain, bleeding, discomfort and painkiller consumption will be recorded. a total of 15 patients will surgically treated with coronally advanced flap (caf) associated with de-epithelialized gingival graft. groups were defined as dgg and dgg+prf: dgg group (n=15): de-epithelialized subepithelial connective tissue grafts + coronally advanced flap dgg+prf group (n=15): de-epithelialized subepithelial connective tissue grafts+ l-platelet rich fibrin + coronally advanced flap

Eligibility criteria:
inclusion criteria of participants were as belows: age \> 18 years systemically healthy and non-smoker full-mouth plaque index and full-mouth gingival index score\< 20% no mucogingival surgery experience at operation area no active periodontal disease patients who have not received orthodontic treatment exclusion criteria of participants were as belows: pregnancy and lactation bruxism or occlusal trauma medical contradictions and for periodontal plastic surgery (i.e. mental disorders) medication intake inclusion criteria of surgical area were as below; presence of at least three single-rooted teeth (anterior-premolar) with rt1 class \[25\] buccal gingival recession defects ≥2 mm in depth keratinized gingival width\<3 mm sufficient oral hygiene (bleeding on probing \<10%, periodontal depth\<3 mm) patients without restoration and/or filling in the gingival recession area absence of non-carious cervical lesions and non-detectable cemento-enamel junction (cej) at the defect sites
pharmacokinetics of zsp1273 in participants with severe kidney disease

Conditions: Kidney Impairment

Summary: this study will assess the effect of severe kidney impairment on the pharmacokinetics (pk), safety and tolerability of zsp1273.


Eligibility criteria:
inclusion criteria: 1. body mass index (bmi) ≥18 to ≤28kg/m2 and total body weight \>50 kg(male) or \>40kg(female) at screening (calculated as a function of measured height and weight according to the formula, bmi = kg / m2 where m2 is height in meters squared); 2. ability to understand and willingness to sign a written informed consent form; participants with normal renal function only: 3. normal physical examination, vital signs, 12-lead ecg, chest x-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-clinically significant. 4. glomerular filtration rate (gfr)≥ 90 ml/min 5. age, bmi, and sex comparable to those of subjects of severe renal impairment participants with severe renal impairment only: 6. diagnosis of ckd (any indicators of renal impairment or gfr \< 60 ml/min/1.73 m2 for more than 3 months) 7. glomerular filtration rate (gfr) between 15-29 ml/min (including boundary) exclusion criteria: 1. participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the investigational drug product or any component of the investigational drug product. 2. participants who donated blood or bleeding profusely (\> 400 ml) in the 3 months. 3. pregnant or lactating women, or women of childbearing age with a positive pregnancy test 4. participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks participants with severe renal impairment only: 5. participants with acute renal failure, or a kidney transplant history; or requiring renal dialysis during the study period; 6. hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥ 160mm hg or diastolic blood pressure ≥ 100mm hg) 7. new york heart association (nyha) class iii or iv congestive heart failure 8. alanine aminotransferase (alt) ≥ 2×uln, aspartate aminotransferase(ast) ≥ 2×uln; serum total bilirubin \> 1.5×uln;
reverse trigger phenotypification and response to ventilatory adjustments

Conditions: Reverse Trigger; Acute Respiratory Distress Syndrome; Mechanical Ventilation

Summary: the goal of this prospective observational study is to describe the incidence of reverse trigger (rt) in mechanically ventilated patients with diagnosis of acute respiratory distress syndrome (ards). the main questions it aims to answer are: * real incidence of rt based on continuous monitoring * the response to mechanical ventilatiory adjustments participants will be included as soon as neuromuscular blockers (nmb)/sedation is stopped or in case of spontaneous respiratory efforts detection, whatever happens first. continuous monitoring will be performed by esophageal manometry until switch to a pressure support (spontaneous) mode, restart of deep sedation/neuromuscular blockers by medical indication, or death. in order to allow detection of possible rt in patients with ongoing sedation/nmb, mechanical ventilator waveforms will be screened every 1-2 hours by investigators and critical care physicians with at least 1 year of specific training in detection of dyssynchronies.

measurements: an esophageal catheter for manometry will be placed as usual practice with confirmation of adequate position with the baydur's occlusion test before recordings. an independent flow sensor and pressure transducer will be placed and connected to a laptop computer to obtain real-time monitoring along with continuous recordings, which then will be off-line analyzed by two experts, for confirmation of rt and characterization. data collection: main cause of the acute respiratory failure and days on mechanical ventilation until enrollment will be collected as well as demographic characteristics, including apache ii, sofa and the previous requirement of prone positioning therapy. at identification of the rt, drugs for sedation and analgesia, time from initiation of mechanical ventilation to rt identification and blood gas analysis will be recorded. ventilatory settings will also be collected, including the control variable of the ventilatory mode (volume or pressure), respiratory rate, received tidal volume in ml/kg of predicted body weight, maximum inspiratory flow, ratio of partial arterial oxygen pressure (po2) to fraction of inspired oxygen (fio2), driving pressure and (positive end-expiratory pressure (peep). data about esophageal pressure related to rt will also be recorded, including the magnitude of pressure swing, phase angle, coefficient of variation, rt phenotype, entrainment ratio and the presence of breath stacking. patient-centered outcomes including length of mechanical ventilation, intensive care and hospital length of stay, and mortality will be followed-up until 60 days.

Eligibility criteria:
inclusion criteria: * diagnosis of ards according to the berlin criteria and added new global definition 2023 * mechanical ventilation exclusion criteria: * \<18 years * tracheostomy status * pneumothorax * tube thoracostomy with air leaks

Keywords: reverse trigger acute respiratory distress syndrome dyssynchony mechanical ventilation
four week performance comparison between two commercially available silicone hydrogel lenses

Conditions: Myopia

Summary: the purpose of this study is to compare the performance of two commercially marketed contact lenses when worn for up to 4 weeks in a daily wear modality.


Eligibility criteria:
inclusion criteria: * habitual spherical soft contact lens wearer who wears a contact lens brand with a recommended replacement schedule of 2 weeks or greater. * have a need for correction in both eyes and be correctable to at least 20/40 distance vision in each eye at the dispense of study lenses. * willing and able to wear spherical contact lenses within the available range of powers. * wears contact lenses at least 5 days per week and at least 10 hours per day, removing them nightly. * other protocol-defined inclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks prior to enrollment. * currently enrolled in any clinical trial. * any use of medications for which contact lens wear could be contraindicated as determined by the investigator. * astigmatism of 1.00d or more. * currently wearing contact lenses in a daily disposable modality. * currently wearing air optix aqua or purevision 2 contact lenses * currently sleeping overnight in contact lenses on an occasional or extended wear basis. * other protocol-defined exclusion criteria may apply.
impact of pd1-lymphocytes in bronchoalveolar lavage of patients with lung cancer

Conditions: Lung Cancer

Summary: the aim of this trial is to assess pd1-lymphocytes in bronchoalveolar lavage in patients with lung cancer, ild and asthma.

in this trial, 20 patients with lung cancer, 10 patients with asthma and 10 patients with interstitial lung disease who have to undergo bronchocospy for medical reasons are enrolled. in each patient, bronchoalveolar lavage is performed to assess pd1-lymphocytes.

Eligibility criteria:
inclusion criteria: * age \>18 years * patients with lung cancer, asthma or ild and indication for bronchoscopy for medical reasons * ability to provide informed consent exclusion criteria: * acute excacerbation in patients with asthma or ild * endoluminal tumor growth or penumonia in patients with lung cancer
the effect of dry needling in patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: research suggests that myofascial trigger points (mtrp) play an important role in explaining pain in patients with musculoskeletal knee disorders. trigger points are usually defined as hypersensitive tender spots within taut bands of skeletal muscles that are painful on muscle stimulation and that usually elicit referred pain. treatment of these trigger points could possibly alleviate symptoms in patients with knee pain. however, literature on the effect of trigger point therapy, dry needling in particular, in patients with musculoskeletal knee disorders is scarce. the purpose of this study is to examine the effect of trigger point therapy (dry needling (dn)) on pain, presence of altered central pain processing, muscle features and gait pattern in patients with knee osteoarthritis (koa). 60 patients with symptomatic koa will participate in this study. they will randomly be allocated in either an experimental group (eg) (dry needling technique) or a placebo group (pg) (sham needling technique). pain (visual analogue scale (vas) \& koa outcome score (koos), muscle features during gait and gait pattern (3d gait analysis and surface electromyography (emg)) and presence of altered central pain processing (central sensitization inventory (csi), quantitative sensory testing (qst)) will be measured at baseline and 15 minutes after the intervention. additionally, pain will be measured 3 days after the intervention. the investigators hypothesize that the effect on the outcome measures will be significantly larger in the eg compared to the pg.


Eligibility criteria:
inclusion criteria: * a minimum age of fifty years old; * diagnosed with koa based on the american college of rheumatology (acr) clinical classification criteria(48), including: * a kellgren-lawrence grade of minimum two on radiography; * at least three months of chronical knee pain. exclusion criteria: * patients suffering from autoimmune and/or neurological disorders * patients who had a major trauma/fracture of the lower limb in the past six months - * patients who experienced other musculoskeletal problems than oa

Keywords: dry needling central pain processing pain emg measurements muscle coactivation gait pattern
pneumostem for the prevention and treatment of severe bpd in premature infants

Conditions: Severe Bronchopulmonary Dysplasia

Summary: this study is to evaluate the efficacy and safety of pneumostem® for the prevention and treatment of severe bronchopulmonary dysplasia (severe bpd) in premature infants. half of subjects will receive pneumostem, while the other half will receive a placebo.

bronchopulmonary dysplasia (bpd) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. pneumostem is intended to prevent and treat bpd by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects.

Eligibility criteria:
inclusion criteria: at screening and randomization 1. 23 weeks to \< 25 weeks of gestational age 2. 500g to 1,250g body weight at birth 3. premature infant within postnatal 13 days of age 4. use ventilator with ventilation rate \>12 breaths/min or oxygen supply \> 25%, or use high frequency ventilator (hfv) at ip administration 1. premature infant within postnatal 5 to 14 days of age 2. no improvement in ventilator setting 24 hours prior to administration of ip exclusion criteria: 1. subject with cyanotic congenital heart disease or non-cyanotic congenital heart disease that can cause heart failure 2. subject with pulmonary hypoplasia, congenital diaphragmatic hernia, or serious lung malformation such as congenital cystic lung disease 3. subject with chromosome disorder with serious malformation (i.e. edward syndrome, patau syndrome, down syndrome, etc.), severe congenital malformation (i.e. hydrocephalus, encephalocele, etc.), or severe congenital infection (i.e., herpes, toxoplasmosis, rubella, syphilis, aids, etc.) 4. subject with serious sepsis as active infection or shock due to sepsis 5. subject with grade 3 or 4 of bilateral intraventricular hemorrhage 6. at screening, subject with active pulmonary hemorrhage or active air leak syndrome 7. subject who underwent/will undergo surgery within 72 hours before/after investigational product (ip) administration 8. subject who is expected to be treated with surfactant within 24 hours prior to ip administration 9. subject who is expected to be allergic to gentamicin (birth mother's allergy for gentamicin will be confirmed). 10. subject who have previously participated in other clinical trials 11. subject who is considered ineligible by investigator due to other medical reasons
posterior reversible encephalopathy syndrome in the critically ill patients

Conditions: Posterior Reversible Encephalopathy Syndrome

Summary: posterior reversible encephalopathy syndrome prospective (pres) registry. data collection using a standardized form : demographic data and data related to the pres, including circumstances of onset, dates and times of onset and of symptoms control, on-scene clinical findings, clinical and radiological features of pres, pre-hospital and hospital care providers, timing of antiepileptic, antihypertensive drugs and supportive treatments, results of etiological investigations, cause of pres, type and dosage of antiepileptic and antihypertensive drugs. dates and times of eeg monitoring, eeg results, radiological and biological investigations. outcomes including vital status and glasgow outcome scale score at icu and hospital discharge, day-90 and 1-year after se and determined based on data in the icu and/or neurologist charts and/or patients phone interview


Eligibility criteria:
inclusion criteria: * age \>= 18 years * posterior reversible encephalopathy syndrome defined as: * combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs and * cerebral imaging abnormalities involving the white matter (brain ct scan hypodensities and/or brain mri hypot1, hyper t2 flair) * intensive care unit admission exclusion criteria: * normal cerebral imaging
integrating machine learning for prognostic prediction in stage i nsclc by ct images and pathological factors

Conditions: Lung Cancer - Non Small Cell

Summary: the investigators retrospectively collected the participants with stage i non-small cell lung cancer (nsclc) patients resected between january 2010 to december 2020 for training and internal validation. the clinical data, preoperative clinical information, laboratory results and ct images were collected. the investigators also collected the disease-free survival time. on the deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. pyradiomics was used to extract the radiomic features. lassocox and rsf were used to select the features. we developed a machine learning-based integrative prognostic model that utilizes radiomic and pathological variables as input using loocv framework. and it was further tested on the internal and external cohorts. discrimination was assessed by using the c-index and area under the receiver operating characteristic curve (auc), ibs, dca.


Eligibility criteria:
inclusion criteria: patients with stage i nsclc (ninth ajcc edition) who underwent curative r0 resections between january 2010 and december 2020 - exclusion criteria: 1. absence of enhanced ct 2. history of lung cancer or synchronous lung cancers 3. follow-up records ≤3 months 4. carcinoma in situ (cis) or minimally invasive nsclc 5. death within 30 days of surgery 6. no pathological slides or reports

Keywords: nsclc, ml, dfs
virtual reality in laryngology

Conditions: Pain Management During Office Laryngeal Procedures

Summary: the purpose of this study is to compare patient's pain and anxiety undergoing laryngeal procedures and esophageal manometry while wearing a vr headset to standard of care. it is hypothesized that patient's using the vr headset during the procedure will have reduced pain and anxiety as compared to their standard of care counterparts because the vr environment will distract them from their procedure.

this is a prospective randomized controlled trial, comparing patients' pain and anxiety experience while wearing a vr headset and receiving standard analgesia during in-office aerodigestive procedures (ioaep) to patients' experience receiving standard analgesia only during ioaep.

Eligibility criteria:
inclusion criteria: * adult patients (18 or older) * patients scheduled for ioaep, including laryngeal biopsies, percutaneous injection laryngoplasty, ktp ablation of hemorrhagic polyps and respiratory papilloma, and transnasal esophagoscopy (tne), and esophageal manometry. exclusion criteria: * patients under 18 years of age * patients unable to consent * non-english-speaking patients * patients who have undergone prior ioaep * patients who have used any psychotropic or analgesic medication within the last 24 hours due to the possible confounding effect on pain or anxiety perception * patients with motion sickness or uncorrected visual impairment (legal blindness) * patients with past medical history of seizures or visual abnormalities
cine-magnetic resonance imaging (mri) detecting intra abdominal adhesions

Conditions: Tissue Adhesions

Summary: official title: sensitivity and predictive value of functional cine magnetic resonance imaging (mri) detecting intra-abdominal adhesions background: adhesions are a frequent problem in abdominal surgery. the formation of adhesions is part of a normal wound healing. however in some patients adhesions cause severe complications such as chronic pain, obstruction and strangulation of the bowel. adhesions can also obstruct access to the peritoneal cavity and complicate reoperations. accurate imaging of adhesions would be of benefit avoiding adhesion related complications at repeated laparotomy or laparoscopy. at present no validated diagnostic tool mapping adhesions exists. purpose: to define the sensitivity and specificity of functional cinemri in detecting and mapping adhesions in patients undergoing reoperation. design: prospective multicenter observational trial primary outcome: sensitivity and specificity of functional mri detecting adhesions to the abdominal wall secondary outcome: sensitivity and specificity of functional mri detecting organ-to-organ adhesions. estimated enrollment: 100 estimated study completion date: dec 2019 estimated primary completion date: dec 2019


Eligibility criteria:
inclusion criteria: * patients with a median abdominal scar due to a previous open abdominal surgical procedures with a length of at least 10 cm and have given written consent. exclusion criteria: * severe claustrophobia. * no mri allowed
(withdrawal) ai-based low-dose 3d-dsa reconstruction

Conditions: Cerebrovascular Disease

Summary: if the participants agree to participate in this study, the participants will undergo two scans (classic 3d-dsa and ps-3d-dsa assisted scan) to compare the imaging effects of both. after the procedure, the investigators will record the radiation exposure and collect dsa images.

although several previous studies have used deep learning methods to reduce 3d-dsa radiation dose, no prospective clinical trial had yet validated the practical application of these models. herein, the investigators introduce a patient-specific generative ai-based low-dose cerebrovascular 3d-dsa image reconstruction method (ps-3d-dsa) to reconstruct 3d-dsa images from ultra-sparse 2d projection views and a prospective cohort is used to validate its efficacy in clinical practice.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. requires 3d-dsa-guided interventional diagnosis or treatment (e.g., cerebral angiography, cerebral artery chemoembolization) and meets operational indications. 3. can understand the study's purpose, procedures, potential risks, and benefits, and voluntarily signs a written informed consent form. exclusion criteria: 1. severe heart or lung disease, such as heart failure or chronic obstructive pulmonary disease (copd). 2. history of high-dose radiation exams or treatments. 3. known allergies or severe adverse reactions to iodine contrast agents or other relevant medications. 4. pregnant or breastfeeding women. 5. severe comorbidities or chronic diseases (e.g., severe diabetes, renal insufficiency). 6. severe mental illness or cognitive impairment preventing understanding of the study procedures or providing informed consent.

Keywords: cerebrovascular ai 3d-dsa